Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Banu K Arun"'
Autor:
Fatma Nihan Akkoc Mustafayev, Diane D. Liu, Angelica M. Gutierrez, John E. Lewis, Nuhad K. Ibrahim, Vicente Valero, Daniel J. Booser, Jennifer K. Litton, Kimberly Koenig, Dihua Yu, Nour Sneige, Banu K. Arun
Publikováno v:
European Journal of Breast Health, Vol 19, Iss 4, Pp 267-273 (2023)
Objective:Risk-reducing therapy with selective estrogen receptor (ER) modulators and aromatase inhibitors reduce breast cancer risk. However, the effects are limited to ER-positive breast cancer. Therefore, new agents with improved toxicity profiles
Externí odkaz:
https://doaj.org/article/007df5a2dfff4116b58ca4a6c94fbe74
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
The Systemic Treatment of Patients with Metastatic Breast Cancer: @ASCO Resource-Stratified Guideline Q and A presents takeways, rationale, and key recommendations based on #JCOGO full guideline for patients by menopausal and marker status.
Externí odkaz:
https://doaj.org/article/0d95c1ed99654766bbd1ea4baf72f52f
Autor:
Taru A. Muranen, Anna Morra, Sofia Khan, Daniel R. Barnes, Manjeet K. Bolla, Joe Dennis, Renske Keeman, Goska Leslie, Michael T. Parsons, Qin Wang, Thomas U. Ahearn, Kristiina Aittomäki, Irene L. Andrulis, Banu K. Arun, Sabine Behrens, Katarzyna Bialkowska, Stig E. Bojesen, Nicola J. Camp, Jenny Chang-Claude, Kamila Czene, Peter Devilee, HEBON investigators, Susan M. Domchek, Alison M. Dunning, Christoph Engel, D. Gareth Evans, Manuela Gago-Dominguez, Montserrat García-Closas, Anne-Marie Gerdes, Gord Glendon, Pascal Guénel, Eric Hahnen, Ute Hamann, Helen Hanson, Maartje J. Hooning, Reiner Hoppe, Louise Izatt, Anna Jakubowska, Paul A. James, Vessela N. Kristensen, Fiona Lalloo, Geoffrey J. Lindeman, Arto Mannermaa, Sara Margolin, Susan L. Neuhausen, William G. Newman, Paolo Peterlongo, Kelly-Anne Phillips, Miquel Angel Pujana, Johanna Rantala, Karina Rønlund, Emmanouil Saloustros, Rita K. Schmutzler, Andreas Schneeweiss, Christian F. Singer, Maija Suvanto, Yen Yen Tan, Manuel R. Teixeira, Mads Thomassen, Marc Tischkowitz, Vishakha Tripathi, Barbara Wappenschmidt, Emily Zhao, Douglas F. Easton, Antonis C. Antoniou, Georgia Chenevix-Trench, Paul D. P. Pharoah, Marjanka K. Schmidt, Carl Blomqvist, Heli Nevanlinna
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-15 (2023)
Abstract We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and
Externí odkaz:
https://doaj.org/article/b25ef8c428ef4ff4ab3dccc937dc88a5
Autor:
Sukh Makhnoon, Angelica M. Gutierrez Barrera, Roland Bassett, Aimaz Afrough, Isabelle Bedrosian, Banu K. Arun
Publikováno v:
The Breast Journal, Vol 2022 (2022)
Background. Patients with unilateral breast cancer carrying pathogenic variants in BRCA1/2 have the option to undergo contralateral prophylactic mastectomy (CPM). However, differences in CPM use and survival outcomes following CPM are poorly understo
Externí odkaz:
https://doaj.org/article/a6b0af19cfa14ba8a1c4881337746306
Autor:
Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, Banu K. Arun, Hyo S. Han, Shannon Puhalla, Yaroslav Shparyk, Erik H. Jakobsen, Meijing Wu, Bruce A. Bach, Dai Feng, Christine K. Ratajczak, David Maag, Véronique Diéras
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (g BRCA )-associated breast cancer defined by hormone recepto
Autor:
Xuan Liu, Zhongqi Ge, Fei Yang, Alejandro Contreras, Sanghoon Lee, Jason B. White, Yiling Lu, Marilyne Labrie, Banu K. Arun, Stacy L. Moulder, Gordon B. Mills, Helen Piwnica-Worms, Jennifer K. Litton, Jeffrey T. Chang
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib f
Externí odkaz:
https://doaj.org/article/c1596f6b174a47a78043a40e8d62cdcd
Autor:
Rachel M. Layman, Heather Lin, Angelica M. Gutierrez Barrera, Meghan S. Karuturi, Clinton Yam, Banu K. Arun
Publikováno v:
Cancer Medicine, Vol 11, Iss 6, Pp 1474-1483 (2022)
Abstract Background BRCA‐associated breast cancers tend to have distinctive features compared to sporadic breast cancers; further characterization can aid in optimizing treatment. Methods The study evaluated a patient cohort with early‐stage estr
Externí odkaz:
https://doaj.org/article/d4ac527a527d4079b8d553509d3f7582
Autor:
Xian Chen, Dong Yang, Jason P. W. Carey, Cansu Karakas, Constance Albarracin, Aysegul A. Sahin, Banu K. Arun, Merih Guray Durak, Mi Li, Mehrnoosh Kohansal, Tuyen N. Bui, Min-Jin Ha, Kelly K. Hunt, Khandan Keyomarsi
Publikováno v:
Cancers, Vol 13, Iss 7, p 1656 (2021)
The identification of biomarker-driven targeted therapies for patients with triple negative breast cancer (TNBC) remains a major clinical challenge, due to a lack of specific targets. Here, we show that cyclin E, a major regulator of G1 to S transiti
Externí odkaz:
https://doaj.org/article/8e8826338e7a4540b09593d085123bfe
Autor:
Akshara Singareeka Raghavendra, Hala F. Alameddine, Clark R. Andersen, Jesse C. Selber, Abenaa M. Brewster, Carlos H. Barcenas, Abigail S. Caudle, Banu K. Arun, Debu Tripathy, Nuhad K. Ibrahim
Publikováno v:
Cancers, Vol 13, Iss 9, p 2050 (2021)
(1) Background: The relatively high rate of contralateral prophylactic mastectomy (CPM) among women with early stage unilateral breast cancer (BC) has raised concerns. We sought to assess the influence of partners, physicians, and the media on the de
Externí odkaz:
https://doaj.org/article/80cd2a0c12b0464d8d8c8f00a6929fe5
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 4 (2012)
Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cance
Externí odkaz:
https://doaj.org/article/2b9a1c013c884108a97e41900dd959dd